Ombitasvir

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of ombitasvir
General
Non-proprietary name Ombitasvir
other names

Dimethyl N , N '- {[(2 S , 5 S ) -1- (4- tert -butylphenyl) pyrrolidine-2,5-diyl] -bis - {[(4,1-phenyleneazanediyl) carbonyl] [(2 S ) -pyrrolidine-2,1-diyl]} [(2 S ) -3-methyl-1-oxobutane-1,2-diyl]} biscarbamate ( IUPAC )

Molecular formula C 50 H 67 N 7 O 7
External identifiers / databases
CAS number 1258226-87-7
PubChem 54767916
ChemSpider 31136214
DrugBank DB09296
Wikidata Q19598175
Drug information
ATC code

J05 AX66

properties
Molar mass 894.11 g mol −1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling
no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Ombitasvir is an antiviral drug for the treatment of hepatitis C sold by Gilead Sciences . It is used in combination with paritaprevir , ritonavir and dasabuvir as Viekira Pak against the hepatitis C virus genotype 1, and with paritaprevir and ritonavir under the name Technivie for the treatment of HCV genotype 4.

Ombitasvir is an NS5A inhibitor .

Individual evidence

  1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
  2. ↑ VIEKIRA PAK ™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for oral use. Full prescribing information . AbbVie Inc., North Chicago, IL 60064. Retrieved July 30, 2015.
  3. ↑ FDA approves Viekira Pak to treat hepatitis C . Food and Drug Administration . 19th December 2014.
  4. ↑ TECHNIVIE ™ (ombitasvir, paritaprevir and ritonavir) tablets, for oral use. Full prescribing information . AbbVie Inc., North Chicago, IL 60064. Archived from the original on January 19, 2019. Retrieved July 28, 2015.
  5. ↑ FDA approves Technivie for treatment of chronic hepatitis C genotype 4 . Food and Drug Administration . July 24, 2015.
  6. ↑ Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel Sigal, David R. Nelson, Darrell Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, Barry Bernstein: Treatment of HCV with ABT-450 / r – Ombitasvir and Dasabuvir with Ribavirin . In: N Engl J Med . 370, 2014, pp. 1594-1603. doi : 10.1056 / NEJMoa1315722 .